STAMBP Inhibidores

Los inhibidores comunes de STAMBP incluyen, entre otros, Bortezomib CAS 179324-69-7, MG-132 [Z-Leu- Leu-Leu-CHO] CAS 133407-82-6, Lactacistina CAS 133343-34-7, Inhibidor de Ubiquitina E1, PYR-41 CAS 418805-02-4 y Ubiquitina CAS 79586-22-4.

The inhibitors listed above primarily target the ubiquitin-proteasome system and deubiquitinating enzymes, which could indirectly influence STAMBP activity. Given STAMBP's involvement in deubiquitination and cell signaling, these compounds are relevant for understanding its function and potential regulation. Proteasome inhibitors like Bortezomib, MG132, Lactacystin, and Clasto-Lactacystin β-Lactone can impact the degradation pathways where STAMBP plays a role.

PYR-41 and Ubiquitin Aldehyde target upstream components of the ubiquitination process, potentially affecting STAMBP's involvement in deubiquitination. Broad-spectrum deubiquitinating enzyme inhibitors such as PR-619 and selective inhibitors like WP1130, IU1, and HBX 19818 might indirectly influence STAMBP's activity by altering the ubiquitin landscape in cells. N-Ethylmaleimide, known for its inhibitory action on various enzymes, could also impact ubiquitination processes relevant to STAMBP. VLX1570, targeting proteasome deubiquitinating activity, might influence the pathways in which STAMBP is involved, particularly in protein degradation.